Some aspects of pharmacological support with antidysrhythmic drugs

Abstract

A high level of morbidity and mortality from cardiovascular diseases remains prevalent in the Russian Federation, despite a decreasing trend that emerged in recent years. Rhythm and conduction disorders play an essential role in the thanatogenesis of cardiovascular pathology, which determines the medical and social significance of their pharmacotherapy. This is indicated by the stable demand for antidysrhythmic drugs from both the state and the population. This is evidenced by high levels of public procurements and retail sales of “drugs for the treatment of cardiovascular diseases,” since patients take this drug group for a long time and often permanently. Our marketing analysis of the antidysrhythmic drugs market used current open data from the State Register of Medicines and the State Register of Maximum Selling Prices and available analytical data. It showed that from 54.5% (metoprolol drugs) to 100% (procainamide drugs) of the market share is occupied by generic drugs made in Russia. The presented analysis confirms the assumption of a significant increase in the share of generic drugs in public procurements. This is associated with the implementation of the drug safety program for vital and essential drugs and the optimization of costs by the state. A priority of the state drug policy in Russia is to monitor the effectiveness and safety throughout its entire life cycle. Moreover, particular importance should be given to the issue of interchangeability, which is regulated by Federal Law No. 1360 dated September 5, 2020, “On the Procedure for Determining the Interchangeability of Medicines for Medical Use.” The annual increase in the share of generic domestic antidysrhythmic drugs on the market poses the problem of selecting the most efficient and safe approach to pharmacotherapy for practicing specialists. The solution may be to develop and implement open automated information systems for the safety profiles of the original and generic antidysrhythmic drugs.

Keywords

cardiovascular diseases / cardiac rhythm and conduction disorders / antidysrhythmic drugs / efficiency and safety of pharmacotherapy / market analysis / generics / interchangeability

References

[1] Ageeva LI. Healthcare in Russia. Moscow: Rosstat; 2019. (In Russ).

[2] Агеева Л.И., Александрова Г.А. Здравоохранение в России. М.: Росстат, 2019.

[3] Ulumbekova GE. Healthcare of Russia: results of activities 2012–2016. Urgent Measures in 2017–2018. ORGZDRAV: news, opinions, training. Bulletin of the Higher School of Economics. 2017;(1):8–12. (In Russ).

[4] Улумбекова Г.Э. Здравоохранение России: итоги деятельности 2012–2016 гг. Неотложные меры в 2017–2018 гг. // ОРГЗДРАВ: Новости. Мнения. Обучение. Вестник ВШОУЗ. 2017. № 1. C. 8–22.

[5] Ulumbekova GE. Healthcare of Russia: 2018–2024 What to do? ORGZDRAV: news, opinions, training. Bulletin of the Higher School of Education. 2018(11):9–17. (In Russ).

[6] Улумбекова Г.Э. Здравоохранение России: 2018–2024 гг. Что надо делать? // ОРГЗДРАВ: новости, мнения, обучение. Вестник ВШОУЗ. 2018. № 1. С. 9–17.

[7] Mazur NA. Sudden death of patients with ischemic heart disease. Moscow: Medicine; 1985. (In Russ).

[8] Мазур Н.А. Внезапная смерть больных ишемической болезнью сердца. М.: Медицина, 1985.

[9] Goldstein S, Bayes-de-Luna A, Gumdo-Soldevila J. Sudden cardiac death. Armonk: Futura; 1994.

[10] Goldstein S., Bayes-de-Luna A., Gumdo-Soldevila J. Sudden cardiac death. Armonk: Futura, 1994.

[11] Medgate.ru/article/ [Internet]. Treatment of cardiac arrhythmias. [access date: 07.12.2020]. Avalible from: http://www.medgate.ru/article/16/117858 (In Russ).

[12] Medgate.ru/article/16/117858/ [интернет]. Лечение нарушений ритма сердца. [дата обращения: 07.12.2020]. Доступ по ссылке: http://www.medgate.ru/article/16/117858/.

[13] Dsm.ru/docs/analytics/ [Internet]. Russian pharmaceutical market: results of 2018. [cited 2020 Dec 07]. Available from: https://dsm.ru/docs/analytics/Annual_report_2018_DSM.pdf (In Russ).

[14] Dsm.ru/docs/analytics/Annual_report_2018_DSM.pdf [интернет]. Фармацевтический рынок России: итоги 2018 г. [дата обращения: 07.12.2020]. Доступ по ссылке: https://dsm.ru/docs/analytics/Annual_report_2018_DSM.pdf.

[15] Dsm.ru/marketing/free-information/analytic-reports/ [Internet] Russian pharmaceutical market. Monthly analytical reviews of the market for the period for 2017 and for 2018, monthly. [cited 2020 Jul 12]. Available from: https://dsm.ru/marketing/free-information/analytic-reports/ (In Russ).

[16] Dsm.ru [интернет]. Фармацевтический рынок России. Ежемесячные аналитические обзоры рынка в период за 2017 год и за 2018 год, помесячно. [дата обращения: 07.12.2020]. Доступ по ссылке: https://dsm.ru/marketing/free-information/analytic-reports/.

[17] Ulumbekova GE, Kalashnikova AV. Analysis of the pharmaceutical market in the Russian Federation ORGZDRAV: news, opinions, training. Bulletin of the Higher School of Education. 2018;(4):53–76. (In Russ).

[18] Улумбекова Г.Э., Калашникова А.В. Анализ рынка лекарственных препаратов в РФ // ОРГЗДРАВ: новости, мнения, обучение. Вестник ВШОУЗ. 2018. № 4. С. 53–76.

[19] Dsm.ru/news/695/ [Internet] Overview of the pharmaceutical segment of pharmaceuticals for 2019. [cited 2020 Dec 07]. Available from: https://dsm.ru/news/695/ (In Russ).

[20] Dsm.ru/news/695/ [интернет]. Обзор аптечного сегмента лекарственных препаратов за 2019 год. [дата обращения: 07.12.2020] Доступ по ссылке: https://dsm.ru/news/695/.

[21] Batishcheva GA, Mubarakshina OA, Kurbatova EI. Original and reproduced drugs in cardiology: problems of interchangeability of bisoprolol drugs. Consilium Medicum. 2016;18(10):50–54. (In Russ).

[22] Батищева Г.А., Мубаракшина О.А., Курбатова Е.И. Оригинальные и воспроизведенные лекарственные препараты в кардиологии: проблемы взаимозаменяемости препаратов бисопролола // Consilium Medicum. 2016. Т. 18, № 10. С. 50–54.

[23] Vyshemirskaya EV, Ganicheva LM. Analysis of consumer preferences when choosing antiarrhythmic drugs. Bulletin of Volgograd State Medical University. 2018;(3):67–68. (In Russ).

[24] Вышемирская Е.В., Ганичева Л.М. Анализ потребительский предпочтений при выборе противоаритмических лекарственных препаратов // Вестник ВолгГМУ. 2018. № 3. С. 67-68.

[25] Dremova NB. Medical and pharmaceutical commodity science: textbook (course). Kursk: Kursk State Medical University; 2005. (In Russ).

[26] Дрёмова Н.Б. Медицинское и фармацевтическое товароведение. Курск: Курский государственный медицинский университет, 2008.

[27] Dsm.ru/docs/analytics/2019_Report_rus_2019.pdf [internet]. Russian pharmaceutical market. [cited 2020 Dec 07]. Available from: https://dsm.ru/docs/analytics/2019_Report_rus_2019.pdf

[28] Dsm.ru/docs/analytics/ [интернет]. Фармацевтический рынок России 2019. [дата обращения: 07.12.2020]. Доступ по ссылке: https://dsm.ru/docs/analytics/2019_Report_rus_2019.pdf.

[29] Romanov BK, Toropova II, Kolesnikova EY. Missuse of drugs. Safety and risk of pharmacotherapy. 2014;(2):28–30. (In Russ).

[30] Романов Б.К., Торопова И.И., Колесникова Е.Ю. Неправильное применение лекарственных средств // Безопасность и риск фармакотерапии. 2014. №. 2. С. 28–30.

RIGHTS & PERMISSIONS

Eco-Vector